JP4897179B2 - グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター - Google Patents

グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター Download PDF

Info

Publication number
JP4897179B2
JP4897179B2 JP2001582286A JP2001582286A JP4897179B2 JP 4897179 B2 JP4897179 B2 JP 4897179B2 JP 2001582286 A JP2001582286 A JP 2001582286A JP 2001582286 A JP2001582286 A JP 2001582286A JP 4897179 B2 JP4897179 B2 JP 4897179B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
use according
disease
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001582286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003532708A (ja
JP2003532708A5 (enExample
Inventor
アナ・マルチネス・ジル
アナ・カストロ・モレラ
マリア・コンセプシオン・ペレス・マルティン
メルセデス・アロンソ・カスコン
イザベル・ドロンソロ・ディアス
フランシスコ・ホセ・モレノ・ムニョス
フランシスコ・ワンドセル・フラド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Priority claimed from PCT/GB2001/002100 external-priority patent/WO2001085685A1/en
Publication of JP2003532708A publication Critical patent/JP2003532708A/ja
Publication of JP2003532708A5 publication Critical patent/JP2003532708A5/ja
Application granted granted Critical
Publication of JP4897179B2 publication Critical patent/JP4897179B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2001582286A 2000-05-11 2001-05-11 グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター Expired - Lifetime JP4897179B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ES200001185A ES2166328B1 (es) 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
ESP200001185ES 2000-05-11
ES200001185ES 2000-05-11
GB0030284.4 2000-12-12
GB0030284A GB0030284D0 (en) 2000-05-11 2000-12-12 Enzyme inhibitors
PCT/GB2001/002100 WO2001085685A1 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3

Publications (3)

Publication Number Publication Date
JP2003532708A JP2003532708A (ja) 2003-11-05
JP2003532708A5 JP2003532708A5 (enExample) 2006-01-05
JP4897179B2 true JP4897179B2 (ja) 2012-03-14

Family

ID=8493477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001582286A Expired - Lifetime JP4897179B2 (ja) 2000-05-11 2001-05-11 グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター

Country Status (5)

Country Link
JP (1) JP4897179B2 (enExample)
CN (1) CN101045715B (enExample)
ES (1) ES2166328B1 (enExample)
GB (1) GB0030284D0 (enExample)
PT (1) PT1286964E (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
AU2007275686B2 (en) * 2006-07-18 2013-10-31 University Of Rochester Thiadiazolidinone derivatives
ES2567753T3 (es) * 2009-07-08 2016-04-26 Baltic Bio Ab Derivados de 1,2,4-tiazolidin-3-ona y su uso en el tratamiento del cáncer
US9371299B2 (en) * 2012-02-24 2016-06-21 Asd Therapeutics Partners, Llc Thiadiazolidinediones as GSK-3 inhibitors
CA2978182A1 (en) * 2015-03-17 2016-09-22 Regeneron Pharmaceuticals, Inc. Amino acid acylation reagents and methods of using the same
CN105330608B (zh) * 2015-10-27 2018-06-26 南方科技大学 脲唑类轴手性化合物及其催化不对称合成方法
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
CN110698380B (zh) * 2019-10-24 2021-01-15 华东理工大学 一种内酰胺衍生物及其制备方法与应用
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863803A (en) * 1957-05-13 1958-12-09 Stauffer Chemical Co Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
GB1115350A (en) * 1966-05-23 1968-05-29 Bayer Ag Thiaimidazolidines
US3534057A (en) * 1968-05-28 1970-10-13 Velsicol Chemical Corp Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
JPS4844432A (enExample) * 1971-03-02 1973-06-26
US3900485A (en) * 1967-02-10 1975-08-19 Velsicol Chemical Corp New substituted 1,2,4-thiadiazolidine-3,5-diones
WO1995017182A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
WO1995034204A1 (de) * 1994-06-13 1995-12-21 Bayer Aktiengesellschaft Bakterizide thiadiazolidinone
US5532256A (en) * 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
WO1997040017A2 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
WO2000038675A1 (en) * 1998-12-23 2000-07-06 Smithkline Beecham Plc Treatment of conditions with a need for the inhibition of gsk-3
WO2001009106A1 (en) * 1999-08-02 2001-02-08 Smithkline Beecham P.L.C. Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301894A (en) * 1964-11-16 1967-01-31 Olin Mathieson S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
JPS58216177A (ja) * 1982-06-10 1983-12-15 Sumitomo Chem Co Ltd フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863803A (en) * 1957-05-13 1958-12-09 Stauffer Chemical Co Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
GB1115350A (en) * 1966-05-23 1968-05-29 Bayer Ag Thiaimidazolidines
US3900485A (en) * 1967-02-10 1975-08-19 Velsicol Chemical Corp New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en) * 1968-05-28 1970-10-13 Velsicol Chemical Corp Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
JPS4844432A (enExample) * 1971-03-02 1973-06-26
WO1995017182A1 (en) * 1993-12-23 1995-06-29 Eli Lilly And Company Protein kinase c inhibitors
US5532256A (en) * 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
WO1995034204A1 (de) * 1994-06-13 1995-12-21 Bayer Aktiengesellschaft Bakterizide thiadiazolidinone
WO1997040017A2 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
WO2000021927A2 (en) * 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
WO2000038675A1 (en) * 1998-12-23 2000-07-06 Smithkline Beecham Plc Treatment of conditions with a need for the inhibition of gsk-3
WO2001009106A1 (en) * 1999-08-02 2001-02-08 Smithkline Beecham P.L.C. Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors

Also Published As

Publication number Publication date
ES2166328B1 (es) 2003-09-16
CN101045715B (zh) 2010-11-24
CN101045715A (zh) 2007-10-03
PT1286964E (pt) 2007-08-08
JP2003532708A (ja) 2003-11-05
GB0030284D0 (en) 2001-01-24
ES2166328A1 (es) 2002-04-01

Similar Documents

Publication Publication Date Title
KR100812407B1 (ko) 글리코겐 신타제 키나제 ｇｓｋ-3의 헤테로사이클릭 억제제
US7232814B2 (en) Use of paullone derivatives for making medicines
EP1119548B1 (en) 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
TWI352084B (en) Gsk-3 inhibitors
JP4897179B2 (ja) グリコーゲンシンターゼキナーゼｇｓｋ−３の複素環インヒビター
Huber-Villaume et al. 2-(Thienothiazolylimino)-1, 3-thiazolidin-4-ones inhibit cell division cycle 25 A phosphatase
NZ298266A (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1, 1-dioxide derivatives, pharmaceutical compositions
AU2006200668B2 (en) Heterocyclic inhibitors of glycogen synthase kinase GSK-3
Makki et al. Synthesis of novel fluorine compounds substituted-4-thiazolidinones derived from rhodanine drug as highly bioactive probes
CA3058687A1 (en) Substituted imidazole salt compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof
EP1867640A1 (en) Agent for treatment of solid tumor
Martínez Gil et al. Heterocyclic inhibitors of glycogen synthase kinase GSK-3
Martínez Gil et al. Enzyme inhibitors
Wandosell et al. Heterocyclic inhibitors of glycogen synthase kinase GSK-3
US8314132B2 (en) 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone and the intermediates for production thereof
KR100758214B1 (ko) 아릴우레이도아세테이트계 화합물, 및 이를 함유하는 퇴행성 뇌질환 예방 또는 치료용 조성물
JP2008538756A (ja) 塩基性窒素を有さない新規チアゾリジノン類、それらの生成及び医薬剤としての使用
HK1111161A (en) Agent for treatment of solid tumor
HK1111162A (en) Agent for treatment of hematopoietic tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080325

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080725

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080825

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111206

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111222

R150 Certificate of patent or registration of utility model

Ref document number: 4897179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term